Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Real-time Estimate Cboe BZX 14:12:08 2024-05-08 EDT 5-day change 1st Jan Change
28.2 USD +1.53% Intraday chart for Pfizer, Inc. +3.66% -2.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Slipping Wednesday Afternoon MT
Pfizer Agrees to Settle 10,000 Zantac Lawsuits Over Alleged Cancer Risks, Bloomberg Reports DJ
Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits MT
Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits MT
Pfizer Reportedly Agrees to Settle Over 10,000 Zantac Cancer Lawsuits MT
Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits, Bloomberg Says MT
Pfizer agrees to settle more than 10,000 Zantac cancer lawsuits - Bloomberg News RE
Pfizer Inc. Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong CI
Evonik expects Q2 core profit in line with Q1, confirms 2024 outlook RE
Pfizer reports patient death in Duchenne gene therapy study RE
BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline MT
Pfizer: Citi analyst appointed Chief Strategy Officer CF
Pfizer Names Andrew Baum as Chief Strategy, Innovation Officer MT
Pfizer Names Andrew Baum Chief Strategy, Innovation Officer DJ
BioNTech says 90% of 2024 revenues will accrue at end of year RE
Pfizer Announces Executive Changes CI
Northeast Pharmaceutical's Unit Gets Nod to Produce Azithromycin for Injection MT
GSK plc : Back on track Our Logo
Wall Street: optimism ahead of NFP, rates ease CF
PFIZER INC : Buy rating from DZ Bank ZD
Morgan Stanley Adjusts Price Target on Pfizer to $29 From $28 MT
Leerink Adjusts Price Target on Pfizer to $29 From $27 MT
BMO Capital Adjusts Pfizer's Price Target to $36 From $33, Keeps Outperform Rating MT
Moderna quarterly sales beat expectations but plummet from previous year RE
Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating MT
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
27.77 USD
Average target price
31.89 USD
Spread / Average Target
+14.85%
Consensus
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. Pfizer, FedEx CEOs Reportedly Among Those Slated to Possibly Meet With President Xi Jinping
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW